Skip to main content
Premium Trial:

Request an Annual Quote

Biovest Takes 9 Percent Stake in MDxHealth

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – MDxHealth today said that as part of its recent private placement, which brought in $11.7 million, investment firm Biovest has obtained a 9 percent stake in the company.

Biovest's president is Rudi Mariën, who is a co-founder and chairman of Innogenetics, a Belgium-based molecular diagnostics firm.

"The company has accomplished an impressive turnaround over the past 12 months, and is now pursuing a strategy that can sustainably generate novel, high value molecular cancer diagnostics," Mariën said in a statement.

MDxHealth completed the private placement earlier this month. It plans to use proceeds to accelerate the development of molecular diagnostic products, set up a CLIA laboratory, and hire a sales and marketing firm in the US.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.